Feasibility, phase I, and pharmacological study of aerosolized liposomal 9-nitro-20(S)-camptothecin in patients with advanced malignancies in the lungs

Ann N Y Acad Sci. 2000:922:352-4. doi: 10.1111/j.1749-6632.2000.tb07063.x.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase I
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adult
  • Aerosols
  • Aged
  • Antineoplastic Agents / administration & dosage*
  • Antineoplastic Agents / adverse effects
  • Antineoplastic Agents / pharmacokinetics
  • Camptothecin / administration & dosage*
  • Camptothecin / adverse effects
  • Camptothecin / analogs & derivatives
  • Camptothecin / pharmacokinetics
  • Drug Administration Schedule
  • Feasibility Studies
  • Female
  • Humans
  • Liposomes
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / metabolism
  • Male
  • Middle Aged

Substances

  • Aerosols
  • Antineoplastic Agents
  • Liposomes
  • rubitecan
  • Camptothecin